title: Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
abstract: OBJECTIVE
  Calcific uraemic arteriolopathy (CUA), also known as calciphylaxis, is a rare but life-threatening condition that almost exclusively affects patients with chronic kidney disease. Several therapies have been employed to treat this disease but with irregular results. We report a prospective case series of eight patients diagnosed with CUA in our unit between 2002 and 2010.
  
  
  METHODS
  The series consisted of eight patients with CUA (including 4 men, 5 dialysis patients and 3 with functioning allografts) who were treated with bisphosphonates. The diagnosis was by clinical suspicion and a confirmatory biopsy. Five patients had a previous history of high calcium-phosphorus product, 6 had a history of high parathyroid hormone levels (>800pg/ml), 4 had undergone parathyroidectomy, 5 had a history of high cumulative doses of steroids, and 6 patients were under dicoumarin treatment. None of the patients were obese or had diabetes mellitus.
  
  
  RESULTS
  In all patients, progression of skin lesions stopped between 2 to 4 weeks after starting bisphosphonate therapy, with no changes in blood levels of calcium and phosphate. Improvement in pain and lesions was faster in patients receiving intravenous ibandronate. All of these patients remained on bisphosphonate treatment for at least 6 months until the wounds healed completely. No recurrences have been observed after follow-up periods between 1 and 9 years. Renal function remained stable in transplant recipients. The treatment was well tolerated and no adverse effects were observed.
  
  
  CONCLUSIONS
  Bisphosphonates could be a new and attractive alternative to treat CUA.
authors.affiliation: Servicio de Nefrología, Hospital Clínic, Barcelona, Spain. vtorre@clinic.ub.es
authors.forename: José V
authors.initials: JV
authors.lastname: Torregrosa
authors.forename: Carlos E
authors.initials: CE
authors.lastname: Durán
authors.forename: Xoana
authors.initials: X
authors.lastname: Barros
authors.forename: Miquel
authors.initials: M
authors.lastname: Blasco
authors.forename: Marta
authors.initials: M
authors.lastname: Arias
authors.forename: Aleix
authors.initials: A
authors.lastname: Cases
authors.forename: Josep M
authors.initials: JM
authors.lastname: Campistol
mesh_terms: D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D000469:Alkaline Phosphatase / Q000097:blood; D001160:Arterioles / Q000473:pathology*; D002115:Calciphylaxis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002118:Calcium / Q000097:blood; D015897:Comorbidity; D004164:Diphosphonates / Q000627:therapeutic use*; D018450:Disease Progression; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000150:complications / Q000601:surgery; D000077557:Ibandronic Acid; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D010710:Phosphates / Q000097:blood; D011446:Prospective Studies; D006435:Renal Dialysis; D000068296:Risedronic Acid; D012867:Skin / Q000098:blood supply / Q000473:pathology; D014511:Uremia / Q000097:blood / Q000150:complications* / Q000601:surgery / Q000628:therapy
chemical_list: D004164:Diphosphonates; D010281:Parathyroid Hormone; D010710:Phosphates; D000469:Alkaline Phosphatase; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium; D000077557:Ibandronic Acid; D019386:Alendronate